Amber Therapeutics – Strategic-Technological Analysis
34 pages · PDF · 20 August 2025 · Licensed single-user copy, watermarked to the buyer
Tactical Military Medical Tech Human Enhancement United Kingdom Belgium
€499 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
Amber Therapeutics is a pioneering European medtech venture at the intersection of bioelectronic innovation and strategic healthcare autonomy. Founded in 2021 as a spin-off from the University of Oxford, the company has rapidly gained attention for developing a “smart” neuromodulation implant to treat mixed urinary incontinence – a widespread condition that, until now, had no effective therapy .
Headquartered in London (UK) with deep academic roots in Oxford and Antwerp, Amber represents a new breed of dual-use technology companies whose biomedical advances carry implications beyond the clinic.
Key questions this report answers
- How does Amber Therapeutics' 'smart' neuromodulation implant treat mixed urinary incontinence through bioelectronic innovation?
- What is the clinical and technology readiness of the implant, and what dual-use relevance does its bioelectronic technology carry beyond the clinic?
- Which research partners in Oxford and Antwerp, clinical customers and markets does the London-based spin-off engage?
- What capability gaps, dependencies and strategic indicators shape Amber's path to scale?
Inside this report
- Executive Summary
- Corporate Identity & Legal Structure
- Strategic Business Profile
- Technology Portfolio Mapping
- Technology Readiness Assessment
- European Strategic Program Participation
- Academic & Research Origins
- Dual-Use Applications & European Market Strategy
- Strategic Partnerships & European Industrial Alliances
- European Market Focus & Operational Domains
- Intellectual Property & European Innovation Assets
- Leadership & European Technical Expertise
- Capability and Gap Analysis
- Strategic Indicators & European Innovation Metrics
Who it's for
Investors screening Amber Therapeutics, competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (20 August 2025). You receive a 34-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Tactical reports · Military Medical Tech · Human Enhancement · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →